Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US3847471014
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG01N6CGW43
GRAL
Grail, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Grail, Inc.
ISIN
US3847471014
TICKER
GRAL
MIC
XNAS
REUTERS
GRAL.OQ
BLOOMBERG
GRAL US
Fri, 05.06.2026       Grail Inc.
US3847471014

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. Grail, Inc. describes itself as a commercial stage healthcare company with a focus on early cancer detection through screening methodology.Fo...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Sun, 31.05.2026       Grail Inc.
US3847471014

The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the New Cancers Detected by the Galleri Test Were in Stages I-IIIMENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Sat, 30.05.2026       Grail Inc.
US3847471014

No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round  Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, RespectivelyGalleri Increased Cancer Detection Rate by F...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.05.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 34,350 shares of GRAIL's common stock to 56 recently hired non-ex...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.05.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., May 26, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9 at 11:20 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 21.05.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., May 21, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3 at 7:35 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 05.05.2026       Grail Inc.
US3847471014

Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access NationwideNew Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 30.04.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., April 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12 at 8:40 a.m. PT. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Grail Inc.
US3847471014

Detailed NHS-Galleri Trial Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation Final PATHFINDER 2 Study Results Will be Presented as a Late-Breaking Abstract in an Oral Presentation More than 174,000 Participants Enrolled Across Both Studies, Demonstrating the Scientific Rigor of Galleri® Clinical Development ProgramMENLO...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Wed, 15.04.2026       Grail Inc.
US3847471014

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at riskNEW YORK, April 15, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial mis...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Grail Inc.
US3847471014

Integration Will Enable Approximately 450 Health Systems to Access the Galleri Test Results Within Their Existing Patient PortalCollaboration With Epic Will Allow Clinicians to Seamlessly Order the Galleri Multi-Cancer Early Detection Test at the Point of CareMENLO PARK, Calif., April 7, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcar...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Grail Inc.
US3847471014

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of GRAIL, Inc. (“GRAIL” or “the Company”) (NASDAQ: GRAL) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose infor...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Grail Inc.
US3847471014

Partnership expands access to breakthrough blood-based cancer screening intoSuperpower's comprehensive health check and personalized plans.SAN FRANCISCO, April 1, 2026 /PRNewswire/ -- Superpower, the first all-in-one proactive health platform, announced a strategic partnership with GRAIL, Inc. (Nasdaq: GRAL) to bring members access to the Galleri®...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Grail Inc.
US3847471014

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, April 1, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial mi...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Grail Inc.
US3847471014

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk NEW YORK, March 25, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial m...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Grail Inc.
US3847471014

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the timeNEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on G...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 04.03.2026       Grail Inc.
US3847471014

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at riskNEW YORK, March 4, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial miss...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 19,500 shares of GRAIL's common stock to 20 recently hired non-e...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 02.03.2026       Grail Inc.
US3847471014

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws.On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "upda...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Tuesday, Mar. 3 at 10:30 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Grail Inc.
US3847471014

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws.On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 24.02.2026       Grail Inc.
US3847471014

SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that cou...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Fri, 20.02.2026       Grail Inc.
US3847471014

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Grail, Inc. (NASDAQ: GRAL). The investigation focuses on Grail’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Grail securities? If you purchased Grail securities and suffered losses on your inve...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Grail Inc.
US3847471014

Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 MillionCompleted Galleri PMA Submission to FDAShared Topline Results from the NHS-Galleri TrialCompleted Analysis of the Full 35k Participant PATHFINDER 2 StudyStrong Financial Position with Cash into 2030MENLO PARK, Calif., Feb. 19, 2026 /PRNe...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.02.2026       Grail Inc.
US3847471014

The Primary Endpoint of Statistically Significant Combined Stage III-IV Reduction Was Not Met, However A Favorable Trend Was Observed Over TimeGRAIL Announces U.S. Sales Force Expansion Based on Strong NHS-Galleri and PATHFINDER 2 Trial ResultsMENLO PARK, Calif. and LONDON, Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare com...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.02.2026       Grail Inc.
US3847471014

MENLO PARK, Calif., Feb. 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter and full year 2025 following the close of market on Thursday, Feb. 19, 2026. Following the release, company mana...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.12.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 12 at 7:30 a.m. PT. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 01.12.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-ex...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 18.11.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Grail Inc.
US3847471014

Q3 U.S. Galleri Revenue Grew 28% Year-Over-Year to $32.6 Million Q3 Galleri Tests Sold Grew 39% Year-Ove...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 04.11.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Nov. 4, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 7th Annual Wolfe Research Healthcare Conference on Tuesday, Nov. 18 at 10:00 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 29.10.2025       Grail Inc.
US3847471014

Analyst Day 2025 Webcast to Begin at 11:00 a.m. ET on November 13th MENLO PARK, Calif., Oct. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approxim...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 20.10.2025       Grail Inc.
US3847471014

One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up Updated Positive Predictive Value of Galleri in This Symptomatic Populati...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Sat, 18.10.2025       Grail Inc.
US3847471014

More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.10.2025       Grail Inc.
US3847471014

Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea W...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 23.09.2025       Grail Inc.
US3847471014

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highligh...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 10.09.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 26.08.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sep. 9 at 1:50 p.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 12.08.2025       Grail Inc.
US3847471014

Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company w...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.07.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on Wednesday, Aug. 13 at 8:30 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.07.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will ho...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.06.2025       Grail Inc.
US3847471014

Cancer Detection and Positive Predictive Value Substantially Higher Than the Previously Published PATHFINDER Study MENLO PARK, Calif., June 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced positive top-line performance and safety results from th...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Fri, 30.05.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., May 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 77,350 shares of GRAIL's common stock to 38 recently hired non-e...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.05.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET. ...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Grail Inc.
US3847471014

Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detec...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will in...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink
Tue, 29.04.2025       Grail Inc.
US3847471014

MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will hos...
Read more
Grail Inc.
Technical Analysis Termsheets Terminal
Permalink